576 related articles for article (PubMed ID: 28371155)
1. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
Guzman CB; Zhang XM; Liu R; Regev A; Shankar S; Garhyan P; Pillai SG; Kazda C; Chalasani N; Hardy TA
Diabetes Obes Metab; 2017 Nov; 19(11):1521-1528. PubMed ID: 28371155
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Kazda CM; Ding Y; Kelly RP; Garhyan P; Shi C; Lim CN; Fu H; Watson DE; Lewin AJ; Landschulz WH; Deeg MA; Moller DE; Hardy TA
Diabetes Care; 2016 Jul; 39(7):1241-9. PubMed ID: 26681715
[TBL] [Abstract][Full Text] [Related]
3. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
Kazda CM; Frias J; Foga I; Cui X; Guzman CB; Garhyan P; Heilmann C; Yang JA; Hardy TA
Diabetes Obes Metab; 2017 Aug; 19(8):1071-1077. PubMed ID: 28191913
[TBL] [Abstract][Full Text] [Related]
4. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.
Kelly RP; Garhyan P; Raddad E; Fu H; Lim CN; Prince MJ; Pinaire JA; Loh MT; Deeg MA
Diabetes Obes Metab; 2015 Apr; 17(4):414-22. PubMed ID: 25656305
[TBL] [Abstract][Full Text] [Related]
5. The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes.
Hædersdal S; Lund A; Maagensen H; Nielsen-Hannerup E; Gasbjerg LS; Rosenkilde MM; Forman JL; van Hall G; Holst JJ; Knop FK; Vilsbøll T
Eur J Endocrinol; 2022 Jan; 186(2):207-221. PubMed ID: 34863038
[TBL] [Abstract][Full Text] [Related]
6. The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes.
Hædersdal S; Lund A; Nielsen-Hannerup E; Maagensen H; Forman JL; Holst JJ; Knop FK; Vilsbøll T
Eur J Endocrinol; 2022 Oct; 187(4):507-518. PubMed ID: 35977072
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy.
Kazierad DJ; Chidsey K; Somayaji VR; Bergman AJ; Calle RA
Diabetes Obes Metab; 2018 Nov; 20(11):2608-2616. PubMed ID: 29923286
[TBL] [Abstract][Full Text] [Related]
8. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
[TBL] [Abstract][Full Text] [Related]
9. Coding variants in
Guzman CB; Duvvuru S; Akkari A; Bhatnagar P; Battioui C; Foster W; Zhang XM; Shankar SS; Deeg MA; Chalasani N; Hardy TA; Kazda CM; Pillai SG
Hepatol Commun; 2018 May; 2(5):561-570. PubMed ID: 29761171
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.
Pettus JH; D'Alessio D; Frias JP; Vajda EG; Pipkin JD; Rosenstock J; Williamson G; Zangmeister MA; Zhi L; Marschke KB
Diabetes Care; 2020 Jan; 43(1):161-168. PubMed ID: 31694861
[TBL] [Abstract][Full Text] [Related]
11. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Hædersdal S; Lund A; Nielsen-Hannerup E; Maagensen H; van Hall G; Holst JJ; Knop FK; Vilsbøll T
Diabetes; 2020 Dec; 69(12):2619-2629. PubMed ID: 33004472
[TBL] [Abstract][Full Text] [Related]
12. Antisense Inhibition of Glucagon Receptor by IONIS-GCGR
Morgan ES; Tai LJ; Pham NC; Overman JK; Watts LM; Smith A; Jung SW; Gajdošík M; Krššák M; Krebs M; Geary RS; Baker BF; Bhanot S
Diabetes Care; 2019 Apr; 42(4):585-593. PubMed ID: 30765435
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
14. Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda CM; Ding Y; Kelly RP; Garhyan P; Shi C; Lim CN; Fu H; Watson DE; Lewin AJ; Landschulz WH; Deeg MA; Moller DE; Hardy TA
Diabetes Care; 2016 Nov; 39(11):e199-e200. PubMed ID: 27926898
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.
Van Gaal L; Souhami E; Zhou T; Aronson R
J Clin Transl Endocrinol; 2014 Jun; 1(2):31-37. PubMed ID: 29159080
[TBL] [Abstract][Full Text] [Related]
16. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.
Kato H; Nagai Y; Ohta A; Tenjin A; Nakamura Y; Tsukiyama H; Sasaki Y; Fukuda H; Ohshige T; Terashima Y; Sada Y; Kondo A; Sasaoka T; Tanaka Y
Diabetes Res Clin Pract; 2015 Jul; 109(1):199-205. PubMed ID: 25934525
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
18. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
20. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
